In this context, glucagon-like peptide-1 receptor (GLP-1R) agonists have been increasingly used in the treatment of pediatric obesity, with evidence supporting their efficacy in reducing body weight, BMI, and improving glycemic control, although gastrointestinal side effects, such as nausea, are common
Reduced Muscle Mass Muscles generate heat
Hence, using PSM provided additional strength to the study results
At the highest dose, orforglipron helped nearly three times as many participants reach near-normal blood sugar versus the highest dose of oral semaglutide
This index was significantly lower, not exceeding 30%, in the case of monotherapy, except for the OV1946 cell line, where the percentage was approximately 60% for ABT-263 and about 50% for olaparib [137]